July 6, 2021 -- Tetherex Pharmaceuticals has obtained an exclusive worldwide license for the development and commercialization of a novel single-cycle adenovirus vaccine platform from the Mayo Clinic. The platform will be used to target multiple infectious diseases beginning with a COVID-19 vaccine.
The single-cycle adenovirus platform was developed to enhance the expression of target antigens to amplify immune responses to infectious disease targets. Tetherex is investigating the technology in a phase I open-label study designed to assess the safety, reactogenicity, and immunogenicity of a single-cycle adenovirus vaccine candidate against COVID-19.
The trial is expected to enroll up to 80 healthy volunteers and includes both a single ascending dose group and multiple dose group via either intramuscular or intranasal administration.
Financial details regarding the license agreement were not disclosed.